|
Market Closed -
Nasdaq
00:00:00 20/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 26.14 USD | +1.04% |
|
-1.80% | -2.39% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1,120B | - | - | - | - | - |
| 616B | - | - | - | - | - |
| 504B | - | - | - | - | - |
| 367B | - | - | - | - | - |
| 360B | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
